A retrospective study comparing a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen (BuEM) versus carmustine, etoposide, cytarabine and melphalan (BEAM) for autologous hematopoietic cell transplant in advanced Hodgkin and non-Hodgkin lymphomas.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Busulfan (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Carmustine; Cytarabine
- Indications Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Nov 2016 New trial record